Dean Y. Li - Jun 18, 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jun 18, 2025
Transactions value $
$0
Form type
4
Date filed
6/23/2025, 05:22 PM
Previous filing
May 1, 2025
Next filing
Jul 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Li Dean Y Director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Jonathan Golightly, attorney-in-fact 2025-06-23 0001837016

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +22K +1.82% $0.00 1.23M Jun 18, 2025 Direct F1, F2
holding RXRX Class A Common Stock 1.42M Jun 18, 2025 By Dean Y. Li Revocable Trust
holding RXRX Class A Common Stock 137K Jun 18, 2025 By Dean Y. Li GRAT
holding RXRX Class A Common Stock 421K Jun 18, 2025 By Dean Y. Li 2021 Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +44K $0.00 44K Jun 18, 2025 Class A Common Stock 44K $5.11 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
F2 Includes 1,132,815 shares of Class A common stock transferred from the Dean Y. Li GRAT on June 10, 2025.
F3 The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.